Hypocalcemia from end-stage renal disease with dialysis

Hypocalcemia from end-stage renal disease with dialysis is an electrolyte and metabolic complication characterized by subnormal serum calcium concentrations in individuals with kidney failure requiring renal replacement therapy Within this dialysis-dependent population, the condition often contributes to chronic kidney disease–mineral and bone disorder (CKD-MBD) and secondary hyperparathyroidism, and it can clinically manifest as neuromuscular irritability, paresthesias, tetany, QT prolongation,...

Hypocalcemia from end-stage renal disease with dialysis is an electrolyte and metabolic complication characterized by subnormal serum calcium concentrations in individuals with kidney failure requiring renal replacement therapy

Hypocalcemia from end-stage renal disease with dialysis is an electrolyte and metabolic complication characterized by subnormal serum calcium concentrations in individuals with kidney failure requiring renal replacement therapy Within this dialysis-dependent population, the condition often contributes to chronic kidney disease–mineral and bone disorder (CKD-MBD) and secondary hyperparathyroidism, and it can clinically manifest as neuromuscular irritability, paresthesias, tetany, QT prolongation,...

Pathophysiologically, it primarily stems from the loss of functional renal parenchyma, leading to impaired conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol), reduced gastrointestinal calcium absorption, and reciprocal calcium-phosphate precipitation driven by phosphate retention

Pathophysiologically, it primarily stems from the loss of functional renal parenchyma, leading to impaired conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol), reduced gastrointestinal calcium absorption, and reciprocal calcium-phosphate precipitation driven by phosphate retention

Within this dialysis-dependent population, the condition often contributes to chronic kidney disease–mineral and bone disorder (CKD-MBD) and secondary hyperparathyroidism, and it can clinically manifest as neuromuscular irritability, paresthesias, tetany, QT prolongation, or cardiac arrhythmias